On September 29, 2016 Transgenomic, Inc. (TBIO) (NASDAQ: TBIO), reported that it has signed agreements with two additional distributors in China and India for its ICEme Mutation Enrichment Kits for cancer genomic testing (Press release, Transgenomic, SEP 29, 2016, View Source [SID:SID1234515504]). The kits incorporate Transgenomic’s Multiplexed ICE COLD-PCR (MX-ICP) technology and are designed to enable virtually any laboratory to conduct high quality DNA mutation detection in cancer patients using plasma, blood or tissue samples and existing sequencing platforms. The new distributors, JoyingBio in China and Biotron Healthcare in India, are important suppliers of advanced life science products in their respective markets.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Asia represents large and growing healthcare sectors, and our ICEme Kits will allow researchers and clinicians in the rapidly expanding markets of China and India to use the sequencing platforms already in their labs to conduct sophisticated genetic analyses to accelerate cancer research and advance patient care," commented Paul Kinnon, President and Chief Executive Officer of Transgenomic. "We decided to work with these new distributors in response to the increasingly robust demand we are seeing in Asia for our ICEme Kits, which we believe reflects the exceptional accuracy, versatility and ease of use of our unique ICP technology."
ICEme technology delivers up to a 500-fold increase in mutation detection compared to most current methods, with levels of detection routinely achievable down to 0.01%. This ultra-high sensitivity enables detection of low level mutations that allow accurate patient monitoring as well as stratification of cancer sub-populations. ICEme Kits work well with most patient samples, including tissue, blood, plasma, urine and other biofluids. The kits are simple to use and work with most of the downstream genomic analytic platforms commonly available in laboratories today. They are easily customizable for use with single mutations or in combination. The current menu includes approximate 20 clinically relevant, actionable mutations that are associated with important cancers such as colorectal, lung, breast and melanoma. Additional mutations are being added on an ongoing basis.
Additional information on the ICEme kits is available at www.transgenomic.com/products/iceme-kits-overview/.
Multiplexed ICE COLD-PCR was originally developed by the laboratory of Dr. Mike Makrigiorgos at the Dana-Farber Cancer Institute, which has exclusively licensed rights to the technology to Transgenomic.